Photo of Kevin R. Loughlin,  MD

Kevin R. Loughlin, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-6325
Fax: (617) 566-3475


kloughlin@partners.org

Kevin R. Loughlin, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Professor, Surgery, Harvard Medical School
  • Director, Urologic Research, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • Cui M, Au JL, Wientjes MG, O'Donnell MA, Loughlin KR, Lu Z. Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts. J Urol 2015. PubMed
  • Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol 2015. PubMed
  • Jedinak A, Curatolo A, Zurakowski D, Dillon S, Bhasin MK, Libermann TA, Roy R, Sachdev M, Loughlin KR, Moses MA. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. BMC Cancer 2015; 15:259. PubMed
  • Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M, . Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2014; 12:1211-9; quiz 1219. PubMed
  • Loughlin KR. Calcium channel blockers and prostate cancer. Urol Oncol 2014. PubMed
  • Loughlin KR. The Hedgehog pathway: potential biomarker and therapeutic applications in urologic malignancies. Urol Oncol 2014. PubMed
  • Prasad SM, Eyre S, Loughlin KR. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival. Hosp Pract (Minneap) 2013; 41:31-9. PubMed
  • Loughlin KR. Re: Potential years of life lost due to urogenital cancer in the United States: trends from 1972 to 2006 based on data from the SEER database: M. H. Kamel, P. C. Moore, N. K. Bissada and S. M. Heshmat. J Urol 2012; 187: 868-871. J Urol 2012; 188:1049; author reply 1050. PubMed
  • Loughlin KR, Prasad MM. Post-prostatectomy urinary incontinence: a confluence of 3 factors. J Urol 2010; 183:871-7. PubMed
  • Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Stroup AM, Wake R, Wei JT. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. J Natl Compr Canc Netw 2010; 8:240-62. PubMed
  • Loughlin KR. Presidential operations. J Am Coll Surg 2009; 209:796-7. PubMed
  • Fernández CA, Wszolek MF, Loughlin KR, Libertino JA, Summerhayes IC, Shuber AP. A novel approach to using matrix metalloproteinases for bladder cancer. J Urol 2009; 182:2188-94. PubMed
  • Loughlin KR. Hypoxia inducible factor (HIF): Its central role in renal cell cancer targeted therapy. Urol Oncol 2009; 27:236-7. PubMed
  • Bassett WW,Bettendorf DM,Lewis JM,Loughlin KR. Chronic periglandular inflammation on prostate needle biopsy does not increase the likelihood of cancer on subsequent biopsy. Urology 2008; 73:845-9. PubMed
  • Loughlin KR. Renal cancer: Genetic directed therapy. Urol Oncol 2009; 27:130. PubMed
  • Loughlin KR. Medical malpractice: the good, the bad, and the ugly. Urol Clin North Am 2008; 36:101-10, vii. PubMed
  • Zinner MJ,Loughlin KR. The evolution of health care in America. Urol Clin North Am 2008; 36:1-10, v. PubMed
  • Loughlin KR. Re: Medical malpractice in American urology: 22-year national review of the impact of caps and implications for contemporary practice: M. H. Hsieh, A. G. Tan and M. V. Meng J Urol 2008; 179: 1944-1949. J Urol 2008; 180:2720-1; author reply 2721. PubMed
  • Loughlin KR. Immunotherapy: a new paradigm for androgen-refractory prostate cancer. Urol Oncol 2008; 26:575. PubMed
  • Roy R,Louis G,Loughlin KR,Wiederschain D,Kilroy SM,Lamb CC,Zurakowski D,Moses MA. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008; 14:6610-7. PubMed
  • Loughlin KR. Understanding intravesical BCG: A window to the future treatment of noninvasive bladder cancer. Urol Oncol 2008; 26:339-40. PubMed
  • Loughlin KR. The current status of medical student urological education in the United States. J Urol 2008; 179:1087-90; discussion 1090-1. PubMed
  • Loughlin KR, Ganatra A. Re: Malignant ureteral obstruction: outcomes after intervention. Have things changed? L. M. Wong, L. K. Cleeve, A. D. Milner and A. G. Pitman. J Urol 2007; 178: 178-183. J Urol 2007; 179:386. PubMed
  • Hong YM, Loughlin KR. Economic impact of tumor markers in bladder cancer surveillance. Urology 2008; 71:131-5. PubMed
  • Zhang JQ, Loughlin KR, Zou KH, Haker S, Tempany CM. Role of endorectal coil magnetic resonance imaging in treatment of patients with prostate cancer and in determining radical prostatectomy surgical margin status: report of a single surgeon's practice. Urology 2007; 69:1134-7. PubMed
  • Silletti JP, Gordon GJ, Bueno R, Jaklitsch M, Loughlin KR. Prostate biopsy: past, present, and future. Urology 2007; 69:413-6. PubMed
  • Duque JL, Loughlin KR, Adam RM, Kantoff P, Mazzucchi E, Freeman MR. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics 2006; 61:401-8. PubMed
  • Loughlin KR. The practice of urologic oncology: some economic realties. Urol Oncol 2012; 30:S5-9. PubMed
  • Loughlin KR. The future of urologic cancer care in the United States: our finest hour or a bridge too far. Urol Oncol 2010; 28:581-4. PubMed
Hide